melatonin has been researched along with Autism Spectrum Disorder in 62 studies
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous study showed that both melatonin supplement and physical exercise intervention could improve sleep quality in children with autism spectrum disorders (ASD) with the increase in endogenous melatonin level." | 9.51 | Study protocol for a randomized controlled trial comparing the effectiveness of physical exercise and melatonin supplement on treating sleep disturbance in children with autism spectrum disorders. ( Cheng, JCH; Ho, AWY; Lai, EWH; Lau, EYY; Lee, PH; Tse, ACY, 2022) |
| "Robust clinical evidence has not been available for melatonin, a drug commonly administered for treating sleep problems of children with autism spectrum disorder (ASD)." | 9.51 | Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial. ( Fukumizu, M; Hamada, I; Hayashi, M; Ishikawa, Y; Mishima, K; Sugioka, H; Takahashi, H; Yamashita, Y; Yotsuya, O, 2022) |
| "A recent 3-month double-blind, placebo-controlled study demonstrated efficacy and safety of pediatric prolonged-release melatonin (PedPRM) for insomnia in children with autism spectrum disorder." | 9.41 | Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder. ( Breddy, J; Findling, RL; Gringras, P; Malow, BA; Maras, A; Nir, T; Schroder, CM; Zisapel, N, 2021) |
| "This study aimed to evaluate the effectiveness of melatonin in treating insomnia in children with autism spectrum disorder (ASD)." | 9.41 | Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A Meta-analysis. ( He, R; Li, F; Li, W; Liu, Z; Shen, H; Wei, L; Xie, X; Xiong, M, 2023) |
| "Clinical evidence is required about the long-term efficacy and safety of melatonin treatment for sleep problems in children with neurodevelopmental disorders (NDDs) who underwent adequate sleep hygiene interventions." | 9.34 | Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. ( Hamada, I; Hayashi, M; Ishikawa, Y; Mishima, K; Nagamitsu, S; Sugioka, H; Takahashi, H; Yamashita, Y; Yotsuya, O; Yuge, K, 2020) |
| "5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2-5 mg) in improving sleep duration and onset." | 9.30 | Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life. ( Breddy, J; Findling, RL; Gringras, P; Malow, BA; Maras, A; Melmed, RD; Nir, T; Schroder, CM; Shahmoon, S; Zisapel, N, 2019) |
| "To assess the efficacy and safety of novel pediatric-appropriate, prolonged-release melatonin minitablets (PedPRM) versus placebo for insomnia in children and adolescents with autism spectrum disorder (ASD), with or without attention-deficit/hyperactivity disorder (ADHD) comorbidity, and neurogenetic disorders (NGD)." | 9.24 | Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. ( Breddy, J; Findling, RL; Frydman-Marom, A; Gringras, P; Nir, T, 2017) |
| "Melatonin preparations are emerging first-line pharmacotherapy for insomnia in children and adolescents with autism spectrum disorder (ASD), but quality, formulation, consistency, dosing, and limited long-term safety data are of concern." | 9.22 | Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder. ( Zisapel, N, 2022) |
| "The role of melatonin has been extensively investigated in pathophysiological conditions, including autism spectrum disorder (ASD)." | 9.12 | Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. ( Anderson, GM; Bellissant, E; Chokron, S; Claustrat, B; Delorme, R; Denis, L; Fougerou-Leurent, C; Franco, P; Kermarrec, S; Lalanne, S; Nir, T; Schroder, CM; Tordjman, S, 2021) |
| "The aim of this review is to clarify the interrelationship between melatonin and autism spectrum disorder (ASD) during fetal development." | 8.98 | The Relationship between Autism Spectrum Disorder and Melatonin during Fetal Development. ( Choi, J; Hong, Y; Jin, Y; Won, J, 2018) |
| "Melatonin is one of the most used pharmacologic treatments for sleep problems in autism spectrum disorder, though its relationship with circadian and sleep parameters is still not well stablished." | 8.31 | Response to Melatonin Treatment in Children With Autism spectrum Disorder and Relationship to Sleep Parameters and Melatonin Levels. ( Garcés, C; Gavela-Pérez, T; Losada-Del Pozo, R; Martinez-Cayuelas, E; Merino-Andreu, M; Soriano-Guillén, L, 2023) |
| "Poor sleep quality is a major problem in patients with autism spectrum disorder (ASD), and is attributed to low melatonin levels." | 8.12 | Improvement of sleep and melatonin in children with autism spectrum disorder after β-1,3/1,6-glucan consumption: An open-label prospective pilot clinical study. ( Abraham, SJ; Balamurugan, M; Dedeepiya, VD; Ikewaki, N; Iwasaki, M; Kandaswamy, RS; Kurosawa, G; Preethy, S; Raghavan, K; Sonoda, T, 2022) |
| "Melatonin is accessed by almost one quarter of children on the autism spectrum in New Zealand, with higher observed rates among females and those aged between 5 and 11 years, of European ethnicity, and presenting with co-occurring mental health conditions." | 8.02 | Melatonin dispensing among New Zealand children aged 0-18 years with autism: a nationwide cross-sectional study. ( Bowden, N; Eggleston, MJF; McLay, LK; Schluter, PJ; Woodford, EC, 2021) |
| "Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with sleep disturbances that may result from abnormalities in melatonin production." | 7.91 | Urinary levels of 6-sulphatoxymelatonin and their associations with sleep disorders and behavioural impairments in children with autism spectrum disorder. ( Babinska, K; Bartakovicova, K; Celusakova, H; Kemenyova, P; Siklenkova, L; Stebelova, K; Szapuova, Z; Vidosovicova, M; Waczulikova, I, 2019) |
| "This study assessed melatonin levels and the dim light melatonin onset (DLMO) in adults with Autism Spectrum Disorder (ASD) and also investigated the relationships between melatonin and objectively measured sleep parameters." | 7.85 | Assessing the Dim Light Melatonin Onset in Adults with Autism Spectrum Disorder and No Comorbid Intellectual Disability. ( Baker, EK; Hazi, A; Prendergast, LA; Richdale, AL, 2017) |
| "Melatonin is an endogenous hormone and can restore gut microbial dysbiosis under various disease conditions." | 5.72 | Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism. ( Cui, Y; Li, XG; Liu, W; Liu, X; Qiu, B; Wang, X; Xiang, G; Yu, M; Zhang, D; Zhang, Y, 2022) |
| "Melatonin has also protective and antioxidant properties, so we can therefore hypothesize that alterations in melatonin's pathways may be one of the causes of the symptomatology of autism." | 5.72 | Role of melatonin in autism spectrum disorders in a male murine transgenic model: Study in the prefrontal cortex. ( Aria, F; Bonini, SA; Bonomini, F; Borsani, E; Giugno, L; Maccarinelli, G; Mastinu, A; Memo, M; Premoli, M; Rezzani, R, 2022) |
| "Many patients with autism spectrum disorders (ASD) show disturbances in their sleep/wake cycle, and may be particularly vulnerable to the impact of circadian disruptors." | 5.56 | Melatonin treatment of repetitive behavioral deficits in the Cntnap2 mouse model of autism spectrum disorder. ( Block, GD; Colwell, CS; Ghiani, CA; Hitchcock, ON; In Kim, Y; Kim, YS; Loh, DH; Luk, SHC; MacDowell Kaswan, ZA; Tahara, Y; Wang, HB, 2020) |
| "Previous study showed that both melatonin supplement and physical exercise intervention could improve sleep quality in children with autism spectrum disorders (ASD) with the increase in endogenous melatonin level." | 5.51 | Study protocol for a randomized controlled trial comparing the effectiveness of physical exercise and melatonin supplement on treating sleep disturbance in children with autism spectrum disorders. ( Cheng, JCH; Ho, AWY; Lai, EWH; Lau, EYY; Lee, PH; Tse, ACY, 2022) |
| "Robust clinical evidence has not been available for melatonin, a drug commonly administered for treating sleep problems of children with autism spectrum disorder (ASD)." | 5.51 | Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial. ( Fukumizu, M; Hamada, I; Hayashi, M; Ishikawa, Y; Mishima, K; Sugioka, H; Takahashi, H; Yamashita, Y; Yotsuya, O, 2022) |
| "Low melatonin levels are a frequent finding in ASD patients." | 5.48 | Low maternal melatonin level increases autism spectrum disorder risk in children. ( Braam, W; Curfs, L; Ehrhart, F; Maas, APHM; Smits, MG, 2018) |
| "Children with neurodevelopmental disorders are at risk of sleep problems, typically difficulty getting to sleep, sleep/wake rhythm disturbances and reduced duration of sleep (insomnia)." | 5.42 | Melatonin for sleep problems in children with neurodevelopmental disorders. ( , 2015) |
| "This study aimed to evaluate the effectiveness of melatonin in treating insomnia in children with autism spectrum disorder (ASD)." | 5.41 | Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A Meta-analysis. ( He, R; Li, F; Li, W; Liu, Z; Shen, H; Wei, L; Xie, X; Xiong, M, 2023) |
| "Clinical evidence is required about the long-term efficacy and safety of melatonin treatment for sleep problems in children with neurodevelopmental disorders (NDDs) who underwent adequate sleep hygiene interventions." | 5.34 | Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders. ( Hamada, I; Hayashi, M; Ishikawa, Y; Mishima, K; Nagamitsu, S; Sugioka, H; Takahashi, H; Yamashita, Y; Yotsuya, O; Yuge, K, 2020) |
| "To assess the efficacy and safety of novel pediatric-appropriate, prolonged-release melatonin minitablets (PedPRM) versus placebo for insomnia in children and adolescents with autism spectrum disorder (ASD), with or without attention-deficit/hyperactivity disorder (ADHD) comorbidity, and neurogenetic disorders (NGD)." | 5.24 | Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. ( Breddy, J; Findling, RL; Frydman-Marom, A; Gringras, P; Nir, T, 2017) |
| "Melatonin preparations are emerging first-line pharmacotherapy for insomnia in children and adolescents with autism spectrum disorder (ASD), but quality, formulation, consistency, dosing, and limited long-term safety data are of concern." | 5.22 | Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder. ( Zisapel, N, 2022) |
| "The role of melatonin has been extensively investigated in pathophysiological conditions, including autism spectrum disorder (ASD)." | 5.12 | Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. ( Anderson, GM; Bellissant, E; Chokron, S; Claustrat, B; Delorme, R; Denis, L; Fougerou-Leurent, C; Franco, P; Kermarrec, S; Lalanne, S; Nir, T; Schroder, CM; Tordjman, S, 2021) |
| " The use of melatonin in children and adolescents with autism spectrum disorder has been well studied and is associated with a positive effect on sleep in this patient group." | 4.98 | [Pharmacotherapy for children and adolescents with sleep disorders: an overview]. ( Grau, K; Plener, PL, 2018) |
| "The aim of this review is to clarify the interrelationship between melatonin and autism spectrum disorder (ASD) during fetal development." | 4.98 | The Relationship between Autism Spectrum Disorder and Melatonin during Fetal Development. ( Choi, J; Hong, Y; Jin, Y; Won, J, 2018) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| "We developed methods for identifying people on the autism spectrum and defined their sleep problems using the key words, "sleep" or "melatonin", or International Classification of Diseases (ICD) codes." | 4.12 | Characterizing sleep disorders in an autism-specific collection of electronic health records. ( Davis, LK; Hucks, D; Johnston, R; Malow, BA; Maxwell-Horn, A; Niarchou, M; Singer, EV; Sutcliffe, JS, 2022) |
| "Poor sleep quality is a major problem in patients with autism spectrum disorder (ASD), and is attributed to low melatonin levels." | 4.12 | Improvement of sleep and melatonin in children with autism spectrum disorder after β-1,3/1,6-glucan consumption: An open-label prospective pilot clinical study. ( Abraham, SJ; Balamurugan, M; Dedeepiya, VD; Ikewaki, N; Iwasaki, M; Kandaswamy, RS; Kurosawa, G; Preethy, S; Raghavan, K; Sonoda, T, 2022) |
| "Melatonin is accessed by almost one quarter of children on the autism spectrum in New Zealand, with higher observed rates among females and those aged between 5 and 11 years, of European ethnicity, and presenting with co-occurring mental health conditions." | 4.02 | Melatonin dispensing among New Zealand children aged 0-18 years with autism: a nationwide cross-sectional study. ( Bowden, N; Eggleston, MJF; McLay, LK; Schluter, PJ; Woodford, EC, 2021) |
| "Autism spectrum disorder (ASD) is a neurodevelopmental condition associated with sleep disturbances that may result from abnormalities in melatonin production." | 3.91 | Urinary levels of 6-sulphatoxymelatonin and their associations with sleep disorders and behavioural impairments in children with autism spectrum disorder. ( Babinska, K; Bartakovicova, K; Celusakova, H; Kemenyova, P; Siklenkova, L; Stebelova, K; Szapuova, Z; Vidosovicova, M; Waczulikova, I, 2019) |
| "This study assessed melatonin levels and the dim light melatonin onset (DLMO) in adults with Autism Spectrum Disorder (ASD) and also investigated the relationships between melatonin and objectively measured sleep parameters." | 3.85 | Assessing the Dim Light Melatonin Onset in Adults with Autism Spectrum Disorder and No Comorbid Intellectual Disability. ( Baker, EK; Hazi, A; Prendergast, LA; Richdale, AL, 2017) |
| "Melatonin is a hormone that facilitates falling asleep and maintaining sleep and is also involved in the endogenous synchronization of internal biological clocks." | 3.11 | [Therapeutic approaches for sleep and rhythms disorders in children with ASD]. ( Broquère, MA; Claustrat, B; Delorme, R; Franco, P; Lecendreux, M; Schröder, CM; Tordjman, S, 2022) |
| "Many types of sleep disorders have been reported in ASD individuals, but still lack a comprehensive study and in-depth analysis." | 2.66 | Understanding the role of sleep and its disturbances in Autism spectrum disorder. ( Brown, GM; Cardinali, DP; Karthikeyan, R; Pandi-Perumal, SR; Shakunthala, V; Spence, DW, 2020) |
| "The consequences of insomnia, including issues with mood, behavior, and cognition, are discussed." | 2.53 | Pediatric Insomnia. ( Brown, KM; Malow, BA, 2016) |
| "Melatonin was prescribed to 52 children, all but one were extended-release preparations." | 1.91 | Sleep related rhythmic movement disorder: phenotypic characteristics and treatment response in a paediatric cohort. ( Benny, A; Hewertson, V; Hill, CM; Joels, H; Joseph, B; Marshall, A; Piantino, C; Postigo, B; Sharpe, A, 2023) |
| "Our study shows that insomnia is most prevalent in individuals with autism with several consequences on children and family behavior and quality of life." | 1.91 | Sleep disturbances in subjects with autism spectrum disorder: A parental perspective. ( Bernardi, K; Bruni, G; Bruni, O; Ferri, R; Panerai, S; Prono, F, 2023) |
| "Melatonin is an endogenous hormone and can restore gut microbial dysbiosis under various disease conditions." | 1.72 | Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism. ( Cui, Y; Li, XG; Liu, W; Liu, X; Qiu, B; Wang, X; Xiang, G; Yu, M; Zhang, D; Zhang, Y, 2022) |
| "Many patients with autism spectrum disorders (ASD) show disturbances in their sleep/wake cycle, and may be particularly vulnerable to the impact of circadian disruptors." | 1.56 | Melatonin treatment of repetitive behavioral deficits in the Cntnap2 mouse model of autism spectrum disorder. ( Block, GD; Colwell, CS; Ghiani, CA; Hitchcock, ON; In Kim, Y; Kim, YS; Loh, DH; Luk, SHC; MacDowell Kaswan, ZA; Tahara, Y; Wang, HB, 2020) |
| "Sleep disorders (SD) are common in autism spectrum disorder (ASD), yet relatively little is known about the potential genetic mechanisms involved in SD and ASD comorbidity." | 1.56 | Brief Report: A Gene Enrichment Approach Applied to Sleep and Autism. ( Abel, EA; Mannin, OR; Marceau, K; Schwichtenberg, AJ, 2020) |
| "Low melatonin levels are a frequent finding in ASD patients." | 1.48 | Low maternal melatonin level increases autism spectrum disorder risk in children. ( Braam, W; Curfs, L; Ehrhart, F; Maas, APHM; Smits, MG, 2018) |
| "Treatment of Autism Spectrum Disorders (ASD) is challenging." | 1.48 | Treating Children with ASD: The Perspective of Caregivers. ( Alessi-Severini, S; Breik, N; Bugden, S; Kuo, IF; Moffat, M, 2018) |
| "Children with neurodevelopmental disorders are at risk of sleep problems, typically difficulty getting to sleep, sleep/wake rhythm disturbances and reduced duration of sleep (insomnia)." | 1.42 | Melatonin for sleep problems in children with neurodevelopmental disorders. ( , 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (40.32) | 24.3611 |
| 2020's | 37 (59.68) | 2.80 |
| Authors | Studies |
|---|---|
| Borsani, E | 1 |
| Bonomini, F | 1 |
| Bonini, SA | 1 |
| Premoli, M | 1 |
| Maccarinelli, G | 1 |
| Giugno, L | 1 |
| Mastinu, A | 1 |
| Aria, F | 1 |
| Memo, M | 1 |
| Rezzani, R | 1 |
| Tse, AC | 1 |
| Lee, PH | 3 |
| Zhang, J | 2 |
| Chan, RC | 1 |
| Ho, AW | 1 |
| Lai, EW | 1 |
| Schröder, CM | 5 |
| Broquère, MA | 1 |
| Claustrat, B | 2 |
| Delorme, R | 4 |
| Franco, P | 2 |
| Lecendreux, M | 1 |
| Tordjman, S | 2 |
| Zisapel, N | 3 |
| Singer, EV | 2 |
| Niarchou, M | 2 |
| Maxwell-Horn, A | 1 |
| Hucks, D | 1 |
| Johnston, R | 1 |
| Sutcliffe, JS | 1 |
| Davis, LK | 2 |
| Malow, BA | 6 |
| Tedroff, K | 1 |
| von Euler, M | 1 |
| Dahlén, E | 1 |
| Tse, ACY | 2 |
| Lau, EYY | 1 |
| Cheng, JCH | 1 |
| Ho, AWY | 1 |
| Lai, EWH | 2 |
| Bartakovicova, K | 2 |
| Kemenyova, P | 2 |
| Belica, I | 1 |
| Janik Szapuova, Z | 1 |
| Stebelova, K | 2 |
| Waczulikova, I | 2 |
| Ostatnikova, D | 1 |
| Babinska, K | 2 |
| Straub, P | 1 |
| Raghavan, K | 1 |
| Dedeepiya, VD | 1 |
| Kandaswamy, RS | 1 |
| Balamurugan, M | 1 |
| Ikewaki, N | 1 |
| Sonoda, T | 1 |
| Kurosawa, G | 1 |
| Iwasaki, M | 1 |
| Preethy, S | 1 |
| Abraham, SJ | 1 |
| Dack, R | 1 |
| Garstang, JJ | 1 |
| Liu, X | 3 |
| Cui, Y | 3 |
| Zhang, Y | 3 |
| Xiang, G | 3 |
| Yu, M | 3 |
| Wang, X | 5 |
| Qiu, B | 3 |
| Li, XG | 3 |
| Liu, W | 3 |
| Zhang, D | 3 |
| Nogueira, HA | 1 |
| de Castro, CT | 1 |
| da Silva, DCG | 1 |
| Pereira, M | 1 |
| Bazin, B | 1 |
| Geoffroy, PA | 1 |
| Benzaquen, H | 1 |
| Maruani, J | 1 |
| Romier, A | 1 |
| Lejoyeux, M | 1 |
| D'ortho, MP | 1 |
| Frija-Masson, J | 1 |
| Xiong, M | 1 |
| Li, F | 1 |
| Liu, Z | 1 |
| Xie, X | 1 |
| Shen, H | 1 |
| Li, W | 1 |
| Wei, L | 1 |
| He, R | 1 |
| Martinez-Cayuelas, E | 1 |
| Merino-Andreu, M | 1 |
| Losada-Del Pozo, R | 1 |
| Gavela-Pérez, T | 1 |
| Garcés, C | 1 |
| Soriano-Guillén, L | 1 |
| Xu, M | 1 |
| Wang, L | 2 |
| Wang, Y | 1 |
| Deng, J | 1 |
| Wang, F | 1 |
| Pan, S | 1 |
| Zhao, Y | 1 |
| Liao, A | 1 |
| Chen, D | 1 |
| Shen, J | 1 |
| Yang, F | 1 |
| Li, Y | 1 |
| Wang, S | 1 |
| Bernardi, K | 1 |
| Prono, F | 1 |
| Bruni, G | 1 |
| Panerai, S | 1 |
| Ferri, R | 1 |
| Bruni, O | 2 |
| Joels, H | 1 |
| Benny, A | 1 |
| Sharpe, A | 1 |
| Postigo, B | 1 |
| Joseph, B | 1 |
| Piantino, C | 1 |
| Marshall, A | 1 |
| Hewertson, V | 1 |
| Hill, CM | 2 |
| Maes, M | 1 |
| Anderson, G | 1 |
| Betancort Medina, SR | 1 |
| Seo, M | 1 |
| Ojala, JO | 1 |
| Pinato, L | 1 |
| Galina Spilla, CS | 1 |
| Markus, RP | 1 |
| da Silveira Cruz-Machado, S | 1 |
| Siklenkova, L | 1 |
| Celusakova, H | 1 |
| Vidosovicova, M | 1 |
| Szapuova, Z | 1 |
| Karthikeyan, R | 2 |
| Cardinali, DP | 2 |
| Shakunthala, V | 1 |
| Spence, DW | 1 |
| Brown, GM | 2 |
| Pandi-Perumal, SR | 2 |
| El-Ansary, A | 1 |
| Hassan, WM | 1 |
| Daghestani, M | 1 |
| Al-Ayadhi, L | 1 |
| Ben Bacha, A | 1 |
| Findling, RL | 3 |
| Maras, A | 2 |
| Breddy, J | 3 |
| Nir, T | 4 |
| Gringras, P | 3 |
| Yan, T | 1 |
| Goldman, RD | 1 |
| Averina, OV | 1 |
| Kovtun, AS | 1 |
| Polyakova, SI | 1 |
| Savilova, AM | 1 |
| Rebrikov, DV | 1 |
| Danilenko, VN | 1 |
| Wu, ZY | 1 |
| Huang, SD | 1 |
| Zou, JJ | 1 |
| Wang, QX | 1 |
| Naveed, M | 1 |
| Bao, HN | 1 |
| Wang, W | 1 |
| Fukunaga, K | 1 |
| Han, F | 1 |
| Wang, HB | 1 |
| Tahara, Y | 1 |
| Luk, SHC | 1 |
| Kim, YS | 1 |
| Hitchcock, ON | 1 |
| MacDowell Kaswan, ZA | 1 |
| In Kim, Y | 1 |
| Block, GD | 1 |
| Ghiani, CA | 1 |
| Loh, DH | 1 |
| Colwell, CS | 1 |
| Yuge, K | 1 |
| Nagamitsu, S | 1 |
| Ishikawa, Y | 2 |
| Hamada, I | 2 |
| Takahashi, H | 2 |
| Sugioka, H | 2 |
| Yotsuya, O | 2 |
| Mishima, K | 2 |
| Hayashi, M | 2 |
| Yamashita, Y | 2 |
| Yenen, AS | 1 |
| Çak, HT | 1 |
| Johnson, KP | 1 |
| Zarrinnegar, P | 1 |
| Lalanne, S | 1 |
| Fougerou-Leurent, C | 1 |
| Anderson, GM | 1 |
| Chokron, S | 1 |
| Bellissant, E | 1 |
| Kermarrec, S | 1 |
| Denis, L | 1 |
| McLay, LK | 1 |
| Schluter, PJ | 1 |
| Eggleston, MJF | 1 |
| Woodford, EC | 1 |
| Bowden, N | 1 |
| Fukumizu, M | 1 |
| Moskaleva, PV | 1 |
| Shnayder, NA | 1 |
| Nasyrova, RF | 1 |
| Banaschewski, T | 1 |
| Fuentes, J | 1 |
| Hvolby, A | 1 |
| Posserud, MB | 1 |
| Baker, EK | 1 |
| Richdale, AL | 1 |
| Hazi, A | 1 |
| Prendergast, LA | 1 |
| Pagan, C | 2 |
| Goubran-Botros, H | 1 |
| Benabou, M | 2 |
| Lemière, N | 1 |
| Murray, K | 1 |
| Amsellem, F | 1 |
| Callebert, J | 2 |
| Chaste, P | 1 |
| Jamain, S | 1 |
| Fauchereau, F | 1 |
| Huguet, G | 2 |
| Maronde, E | 2 |
| Leboyer, M | 2 |
| Launay, JM | 1 |
| Bourgeron, T | 2 |
| Won, J | 2 |
| Jin, Y | 2 |
| Choi, J | 2 |
| Park, S | 1 |
| Lee, TH | 1 |
| Lee, SR | 1 |
| Chang, KT | 1 |
| Hong, Y | 2 |
| Frydman-Marom, A | 1 |
| Howes, OD | 1 |
| Rogdaki, M | 1 |
| Findon, JL | 1 |
| Wichers, RH | 1 |
| Charman, T | 1 |
| King, BH | 1 |
| Loth, E | 1 |
| McAlonan, GM | 1 |
| McCracken, JT | 1 |
| Parr, JR | 1 |
| Povey, C | 1 |
| Santosh, P | 1 |
| Wallace, S | 1 |
| Simonoff, E | 1 |
| Murphy, DG | 1 |
| Grau, K | 1 |
| Plener, PL | 1 |
| Rolland, T | 1 |
| Leblond, CS | 1 |
| Millot, GA | 1 |
| Anagnostou, E | 1 |
| Braam, W | 1 |
| Ehrhart, F | 1 |
| Maas, APHM | 1 |
| Smits, MG | 1 |
| Curfs, L | 1 |
| Breik, N | 1 |
| Kuo, IF | 1 |
| Bugden, S | 1 |
| Moffat, M | 1 |
| Alessi-Severini, S | 1 |
| Parker, A | 2 |
| Beresford, B | 2 |
| Dawson, V | 2 |
| Elphick, H | 2 |
| Fairhurst, C | 2 |
| Hewitt, C | 2 |
| Scantlebury, A | 2 |
| Spiers, G | 2 |
| Thomas, M | 2 |
| Wright, K | 1 |
| Mcdaid, C | 2 |
| Abel, EA | 1 |
| Schwichtenberg, AJ | 1 |
| Mannin, OR | 1 |
| Marceau, K | 1 |
| Johansson, AEE | 1 |
| Dorman, JS | 1 |
| Chasens, ER | 1 |
| Feeley, CA | 1 |
| Devlin, B | 1 |
| Missig, G | 1 |
| McDougle, CJ | 1 |
| Carlezon, WA | 1 |
| Melmed, RD | 1 |
| Shahmoon, S | 1 |
| Brown, KM | 1 |
| Gevi, F | 1 |
| Zolla, L | 1 |
| Gabriele, S | 1 |
| Persico, AM | 1 |
| Hellmer, K | 1 |
| Nyström, P | 1 |
| Cuomo, BM | 1 |
| Vaz, S | 1 |
| Lee, EAL | 1 |
| Thompson, C | 1 |
| Rogerson, JM | 1 |
| Falkmer, T | 1 |
| Goldman, SE | 1 |
| Alder, ML | 1 |
| Burgess, HJ | 1 |
| Corbett, BA | 1 |
| Hundley, R | 1 |
| Wofford, D | 1 |
| Fawkes, DB | 1 |
| Laudenslager, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities[NCT01906866] | Phase 3 | 125 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Phase II/III Clinical Trial of NPC-15 - Verification of the Efficacy for Sleep Disorders of Children With Autism Spectrum Disorders -[NCT02757066] | Phase 2/Phase 3 | 196 participants (Actual) | Interventional | 2016-06-16 | Completed | ||
| Examining the Association Between Physical Activity and Sleep Quality in Children With Autism Spectrum Disorder Using Melatonin-mediated Mechanism Model: A Randomized Controlled Trial[NCT03348982] | 32 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | |||
| Gut Mobilization With Oral Administration of Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Months in Chronically Constipated Autistic Children.[NCT05025553] | 21 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
questionnaire - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on sleep latency as derived from a Sleep and Nap Diary after 13 weeks of double-blind treatment (NCT01906866)
Timeframe: 13 weeks
| Intervention | minutes (Mean) |
|---|---|
| Circadin 2/5/10 mg | -37.77 |
| Placebo | -12.57 |
Total Sleep Time - To compare the treatment effect of Circadin® 2/5 mg minitablets to that of placebo on total sleep time (TST) as assessed by the Sleep and Nap Diary after 13 weeks of double-blind treatment (NCT01906866)
Timeframe: 13 weeks
| Intervention | minutes (Mean) |
|---|---|
| Circadin 2/5/10 mg | 51.03 |
| Placebo | 18.71 |
21 reviews available for melatonin and Autism Spectrum Disorder
| Article | Year |
|---|---|
Assessing the potential for drug interactions and long term safety of melatonin for the treatment of insomnia in children with autism spectrum disorder.
Topics: Adolescent; Autism Spectrum Disorder; Child; Delayed-Action Preparations; Drug Interactions; Humans; | 2022 |
Melatonin for sleep disorders in people with autism: Systematic review and meta-analysis.
Topics: Autism Spectrum Disorder; Autistic Disorder; Humans; Melatonin; Polysomnography; Sleep; Sleep Wake D | 2023 |
Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A Meta-analysis.
Topics: Autism Spectrum Disorder; Child; Humans; Melatonin; Sleep Duration; Sleep Initiation and Maintenance | 2023 |
Integrating Autism Spectrum Disorder Pathophysiology: Mitochondria, Vitamin A, CD38, Oxytocin, Serotonin and Melatonergic Alterations in the Placenta and Gut.
Topics: ADP-ribosyl Cyclase 1; Autism Spectrum Disorder; Female; Humans; Melatonin; Mitochondria; Oxytocin; | 2019 |
Dysregulation of Circadian Rhythms in Autism Spectrum Disorders.
Topics: Autism Spectrum Disorder; Chronobiology Disorders; Circadian Rhythm; Humans; Melatonin; Sleep Wake D | 2019 |
Understanding the role of sleep and its disturbances in Autism spectrum disorder.
Topics: Autism Spectrum Disorder; Central Nervous System Depressants; Child; Humans; Melatonin; Sleep Wake D | 2020 |
Autism spectrum disorder (ASD): Disturbance of the melatonin system and its implications.
Topics: Animals; Autism Spectrum Disorder; Circadian Rhythm; Humans; Melatonin; Pineal Gland; Signal Transdu | 2020 |
Melatonin and Circadian Rhythm in Autism Spectrum Disorders.
Topics: Autism Spectrum Disorder; Circadian Rhythm; Humans; Melatonin | 2020 |
Autism Spectrum Disorder and Sleep.
Topics: Adolescent; Autism Spectrum Disorder; Child; Humans; Melatonin; Sleep; Sleep Initiation and Maintena | 2021 |
Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder.
Topics: Administration, Oral; Adult; Autism Spectrum Disorder; Biological Availability; Child; Child, Presch | 2021 |
[Association of polymorphic variants of DDC (AADC), AANAT and ASMT genes encoding enzymes for melatonin synthesis with the higher risk of neuropsychiatric disorders].
Topics: Acetylserotonin O-Methyltransferase; Aromatic-L-Amino-Acid Decarboxylases; Arylalkylamine N-Acetyltr | 2021 |
Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
Topics: Anxiety; Autism Spectrum Disorder; Circadian Clocks; Circadian Rhythm; Fragile X Mental Retardation | 2017 |
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2018 |
[Pharmacotherapy for children and adolescents with sleep disorders: an overview].
Topics: Adolescent; Autism Spectrum Disorder; Child; Combined Modality Therapy; Comorbidity; Cross-Sectional | 2018 |
The Relationship between Autism Spectrum Disorder and Melatonin during Fetal Development.
Topics: Animals; Autism Spectrum Disorder; Circadian Rhythm; Female; Fetal Development; Humans; Maternal Exp | 2018 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Oral melatonin for non-respiratory sleep disturbance in children with neurodisabilities: systematic review and meta-analyses.
Topics: Actigraphy; Autism Spectrum Disorder; Child; Humans; Melatonin; Sleep Wake Disorders; Treatment Outc | 2019 |
Sleep as a translationally-relevant endpoint in studies of autism spectrum disorder (ASD).
Topics: Animals; Autism Spectrum Disorder; Circadian Rhythm; Disease Models, Animal; Endpoint Determination; | 2020 |
Outcome domains and outcome measures used in studies assessing the effectiveness of interventions to manage non-respiratory sleep disturbances in children with neurodisabilities: a systematic review.
Topics: Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Depr | 2019 |
Pediatric Insomnia.
Topics: Actigraphy; Adolescent; Amines; Anti-Anxiety Agents; Autism Spectrum Disorder; Central Nervous Syste | 2016 |
Effectiveness of Sleep-Based Interventions for Children with Autism Spectrum Disorder: A Meta-Synthesis.
Topics: Autism Spectrum Disorder; Behavior Therapy; Child; Early Medical Intervention; Humans; Melatonin; Sl | 2017 |
8 trials available for melatonin and Autism Spectrum Disorder
| Article | Year |
|---|---|
[Therapeutic approaches for sleep and rhythms disorders in children with ASD].
Topics: Adolescent; Autism Spectrum Disorder; Child; Humans; Melatonin; Quality of Life; Sleep; Sleep Initia | 2022 |
Study protocol for a randomized controlled trial comparing the effectiveness of physical exercise and melatonin supplement on treating sleep disturbance in children with autism spectrum disorders.
Topics: Autism Spectrum Disorder; Child; Exercise; Humans; Melatonin; Randomized Controlled Trials as Topic; | 2022 |
Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder.
Topics: Adolescent; Aged, 80 and over; Autism Spectrum Disorder; Child; Double-Blind Method; Humans; Melaton | 2021 |
Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders.
Topics: Adolescent; Autism Spectrum Disorder; Child; Female; Humans; Japan; Male; Melatonin; Neurodevelopmen | 2020 |
Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial.
Topics: Autism Spectrum Disorder; Child; Humans; Melatonin; Sleep; Sleep Hygiene; Sleep Wake Disorders | 2022 |
Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous | 2017 |
Study protocol for a randomised controlled trial examining the association between physical activity and sleep quality in children with autism spectrum disorder based on the melatonin-mediated mechanism model.
Topics: Autism Spectrum Disorder; Child; Exercise; Humans; Melatonin; Randomized Controlled Trials as Topic; | 2018 |
Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver's Quality of Life.
Topics: Adolescent; Autism Spectrum Disorder; Caregivers; Central Nervous System Depressants; Child; Child B | 2019 |
33 other studies available for melatonin and Autism Spectrum Disorder
| Article | Year |
|---|---|
Role of melatonin in autism spectrum disorders in a male murine transgenic model: Study in the prefrontal cortex.
Topics: Animals; Autism Spectrum Disorder; Brain; Humans; Male; Melatonin; Mice; Mice, Transgenic; Prefronta | 2022 |
Effects of exercise on sleep, melatonin level, and behavioral functioning in children with autism.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Exercise; Humans; Melatonin; Sleep; Sleep Wake D | 2022 |
Characterizing sleep disorders in an autism-specific collection of electronic health records.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Autistic Disorder; Child; Electronic Health Records; Hu | 2022 |
Melatonin usage in children and young adults, a registry-based cohort study.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Cohort S | 2022 |
Sleep Problems and 6-Sulfatoxymelatonin as Possible Predictors of Symptom Severity, Adaptive and Maladaptive Behavior in Children with Autism Spectrum Disorder.
Topics: Autism Spectrum Disorder; Child; Humans; Melatonin; Sleep; Sleep Wake Disorders | 2022 |
Investigating the genetic pathways of insomnia in Autism Spectrum Disorder.
Topics: Autism Spectrum Disorder; Child; Circadian Rhythm; Humans; Melatonin; Sleep; Sleep Initiation and Ma | 2022 |
Improvement of sleep and melatonin in children with autism spectrum disorder after β-1,3/1,6-glucan consumption: An open-label prospective pilot clinical study.
Topics: Animals; Autism Spectrum Disorder; beta-Glucans; Glucans; Humans; Melatonin; Pilot Projects; Prospec | 2022 |
Use of melatonin: a single-centre audit.
Topics: Adolescent; Autism Spectrum Disorder; Child; Humans; Melatonin; Neurodevelopmental Disorders; Sleep | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Rescue of social deficits by early-life melatonin supplementation through modulation of gut microbiota in a murine model of autism.
Topics: Akkermansia; Animals; Autism Spectrum Disorder; Autistic Disorder; Dietary Supplements; Disease Mode | 2022 |
Continuous positive airway pressure as an accurate marker for non-24-hour sleep-wake rhythm disorder.
Topics: Autism Spectrum Disorder; Circadian Rhythm; Continuous Positive Airway Pressure; Humans; Male; Melat | 2023 |
Response to Melatonin Treatment in Children With Autism spectrum Disorder and Relationship to Sleep Parameters and Melatonin Levels.
Topics: Adolescent; Autism Spectrum Disorder; Child; Circadian Rhythm; Humans; Melatonin; Sleep; Treatment O | 2023 |
Melatonin ameliorates sleep-wake disturbances and autism-like behaviors in the Ctnnd2 knock out mouse model of autism spectrum disorders.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Melatonin; Mice; Mice, Knockout; Sleep; Sleep | 2023 |
Sleep disturbances in subjects with autism spectrum disorder: A parental perspective.
Topics: Autism Spectrum Disorder; Child; Humans; Melatonin; Parents; Quality of Life; Retrospective Studies; | 2023 |
Sleep related rhythmic movement disorder: phenotypic characteristics and treatment response in a paediatric cohort.
Topics: Autism Spectrum Disorder; Child; Female; Humans; Male; Melatonin; Movement Disorders; Parasomnias; R | 2023 |
Urinary levels of 6-sulphatoxymelatonin and their associations with sleep disorders and behavioural impairments in children with autism spectrum disorder.
Topics: Adolescent; Autism Spectrum Disorder; Case-Control Studies; Child; Child, Preschool; Humans; Melaton | 2019 |
Preliminary evaluation of a novel nine-biomarker profile for the prediction of autism spectrum disorder.
Topics: Adolescent; Autism Spectrum Disorder; Biomarkers; Case-Control Studies; Caspase 7; Child; Child, Pre | 2020 |
Melatonin for children with autism spectrum disorder.
Topics: Autism Spectrum Disorder; Behavior Therapy; Child; Humans; Melatonin; Quality of Life; Sleep Initiat | 2020 |
The bacterial neurometabolic signature of the gut microbiota of young children with autism spectrum disorders.
Topics: Autism Spectrum Disorder; Bacteria; Butyric Acid; Child, Preschool; Cohort Studies; Feces; Female; G | 2020 |
Melatonin treatment of repetitive behavioral deficits in the Cntnap2 mouse model of autism spectrum disorder.
Topics: Animals; Autism Spectrum Disorder; Behavior, Animal; Central Nervous System Depressants; Circadian R | 2020 |
Melatonin dispensing among New Zealand children aged 0-18 years with autism: a nationwide cross-sectional study.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Child; Child, Preschool; Cross-Sectional St | 2021 |
Autism Spectrum Disorder patients may be susceptible to COVID-19 disease due to deficiency in melatonin.
Topics: Autism Spectrum Disorder; Circadian Rhythm; COVID-19; Disease Susceptibility; Genetic Variation; Hum | 2021 |
Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders.
Topics: Adolescent; Autism Spectrum Disorder; Child; Humans; Melatonin; Quality of Life; Sleep; Sleep Initia | 2021 |
Assessing the Dim Light Melatonin Onset in Adults with Autism Spectrum Disorder and No Comorbid Intellectual Disability.
Topics: Adult; Anxiety; Autism Spectrum Disorder; Circadian Rhythm; Depression; Female; Humans; Male; Melato | 2017 |
Disruption of melatonin synthesis is associated with impaired 14-3-3 and miR-451 levels in patients with autism spectrum disorders.
Topics: 14-3-3 Proteins; Acetylserotonin O-Methyltransferase; Adolescent; Adult; Arylalkylamine N-Acetyltran | 2017 |
Heritability of the melatonin synthesis variability in autism spectrum disorders.
Topics: Adolescent; Adult; Arylalkylamine N-Acetyltransferase; Autism Spectrum Disorder; Child; Endophenotyp | 2017 |
Low maternal melatonin level increases autism spectrum disorder risk in children.
Topics: Adult; Autism Spectrum Disorder; Case-Control Studies; Child; Female; Gene-Environment Interaction; | 2018 |
Treating Children with ASD: The Perspective of Caregivers.
Topics: Adolescent; Autism Spectrum Disorder; Caregivers; Central Nervous System Depressants; Child; Female; | 2018 |
Brief Report: A Gene Enrichment Approach Applied to Sleep and Autism.
Topics: Autism Spectrum Disorder; Autistic Disorder; Circadian Rhythm; Comorbidity; Databases, Genetic; Dopa | 2020 |
Variations in Genes Related to Sleep Patterns in Children With Autism Spectrum Disorder.
Topics: Adolescent; Autism Spectrum Disorder; Child; Child, Preschool; Circadian Rhythm; Comorbidity; Female | 2019 |
Melatonin for sleep problems in children with neurodevelopmental disorders.
Topics: Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Humans; Hypnotics an | 2015 |
Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism.
Topics: Autism Spectrum Disorder; Biomarkers; Case-Control Studies; Child; Child, Preschool; Chromatography, | 2016 |
Infant acetylcholine, dopamine, and melatonin dysregulation: Neonatal biomarkers and causal factors for ASD and ADHD phenotypes.
Topics: Acetylcholine; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Biomarkers; | 2017 |
Characterizing Sleep in Adolescents and Adults with Autism Spectrum Disorders.
Topics: Actigraphy; Adolescent; Adult; Autism Spectrum Disorder; Cross-Sectional Studies; Female; Humans; Hy | 2017 |